Everyone wants to talk about the models. Almost no one wants to talk about the data feeding them.
That's becoming the uncomfortable truth at the center of AI-driven drug discovery, an industry that has raised billions on the promise that machine learning can compress a process that traditionally takes a decade and billions of dollars into something faster and cheaper.
The models keep getting more sophisticated.
In many cases, the results haven't kept pace.
According to a growing number of researchers, the reason is less glamorous than algorithm design. It comes down to biological data quality.
Garbage in, garbage out isn't a new idea in computing. In drug discovery, however, the consequences are far greater than a poor recommendation engine.
The hype outpaced the inputs
Drug discovery produces data that is messy by nature.
Cell assays vary from batch to batch. Laboratory conditions differ across institutions. Structural biology datasets can be incomplete or inconsistently annotated.
None of this surprises biologists.
Yet these realities are often overlooked in presentations showcasing AI models trained on carefully curated benchmark datasets.
That creates a gap between impressive research papers and real-world performance.
A model trained on clean, well-labelled data may perform exceptionally in testing, then struggle when confronted with the complexity and variability of genuine biological research.
Why this matters now
The AI drug discovery sector has attracted enormous investment from venture capital firms and pharmaceutical companies over the past five years.
Major partnerships have been built around the promise of accelerating drug development.
At the same time, several high-profile setbacks, including AI-designed drug candidates failing during clinical development, have reminded the industry that predicting molecular behaviour on a computer is very different from predicting what happens inside a living organism.
That distinction is changing priorities.
Rather than chasing ever-larger models, many researchers now argue that the greatest returns will come from generating better experimental data, improving validation pipelines and bringing machine learning teams closer to wet-lab scientists.
In other words, the bottleneck is becoming biological rather than computational.
That's a less exciting story than bigger models and faster chips, but it may prove far more important.
Where the competitive advantage is shifting
This change also reshapes where long-term value sits within AI drug discovery.
If foundation models become increasingly commoditised, competitive advantage may belong not to the companies with the largest models, but to those with the highest-quality proprietary biological datasets.
That elevates data generation, laboratory automation and validation infrastructure alongside AI itself.
For pharmaceutical companies and biotech startups, it means investing in experimental science as aggressively as software engineering.
For AI vendors, partnerships with universities, hospitals and research organisations capable of producing rigorously validated biological data may become more valuable than marginal improvements in benchmark performance.
It's a quieter shift than the headlines surrounding frontier AI models.
It may also be the one that determines who ultimately succeeds.
What This Means for Miami
Miami's life sciences and AI sectors remain smaller than those of Boston or the Bay Area, but that could become an advantage.
As the industry shifts its focus from model size to data quality, institutions such as the University of Miami and Florida International University, together with the region's growing biotech and health-tech startups, have an opportunity to compete through rigorous research rather than sheer computing scale.
For local investors, the lesson is equally important. Evaluating AI drug discovery companies increasingly means examining data provenance, validation standards and scientific methodology alongside model architecture.
For Miami's emerging health-tech ecosystem, credible, well-documented biological datasets may become one of the region's most valuable competitive assets as AI continues to reshape biomedical research.
